Home Featured Page 131

Featured

Latest

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

FDA Grants Ehave Consent to Proceed With Its Clinical Study on...

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Silo Pharma Announces Stock Repurchase Program

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical...

Kabir Nath: Our Mission, Progress and Future Perspectives

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression...

PT385 – Relationships, Conviviality, and The Strength of Empathic Attunement

Kabir Nath: our mission, progress and future perspectives

EDITOR PICKS

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Numinus Receives Clinical Trial Application Approval from Health Canada for Experiential...

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to...

FDA Grants Ehave Consent to Proceed With Its Clinical Study on...

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Silo Pharma Announces Stock Repurchase Program

Apex Labs Granted Approval for 294 Patient Take Home Psilocybin Clinical...

Kabir Nath: Our Mission, Progress and Future Perspectives

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression...

PT385 – Relationships, Conviviality, and The Strength of Empathic Attunement

Kabir Nath: our mission, progress and future perspectives

EDITOR PICKS

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY